Duncan Gallagher Sells 4,500 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of Health Catalyst stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $6.93, for a total transaction of $31,185.00. Following the transaction, the director now directly owns 69,938 shares in the company, valued at $484,670.34. This trade represents a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Duncan Gallagher also recently made the following trade(s):

• On Monday, December 23rd, Duncan Gallagher sold 4,500 shares of Health Catalyst stock. The stock was sold at an average price of $6.98, for a total transaction of $31,410.00.

Health Catalyst Trading Up 1.1 %

Shares of HCAT stock opened at $7.42 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market capitalization of $451.51 million, a P/E ratio of -5.50 and a beta of 1.31. The company has a 50 day moving average price of $7.86 and a 200 day moving average price of $7.48. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same quarter last year, the firm posted ($0.22) EPS. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities research analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Analysts Set New Price Targets

HCAT has been the topic of a number of analyst reports. Stephens lifted their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Royal Bank of Canada lifted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Evercore ISI lifted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Finally, Citigroup lifted their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $11.59.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HCAT. First Light Asset Management LLC grew its holdings in Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after acquiring an additional 3,221,408 shares in the last quarter. Millennium Management LLC grew its holdings in Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Nepsis Inc. grew its holdings in Health Catalyst by 67.9% during the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after acquiring an additional 851,448 shares in the last quarter. Fred Alger Management LLC purchased a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $6,858,000. Finally, Portolan Capital Management LLC purchased a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $5,402,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.